Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide pretreatment before robotic-assisted radical prostatectomy in localized high-risk prostate cancer
2024-514786-19-01Phase 4Authorised
- Sponsor
- Biobizkaia Health Research Institute
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Biobizkaia Health Research Institute. Planned start Sep 2024; status: authorised.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-514786-19-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514786-19-01.